Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509156 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Injection in Cancer Survivors
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT02509156 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 46 participants.
The verdict
NCT02509156, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC). The secondary purpose of this study is to obtain preliminary evidence for therapeutic efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV dysfunction secondary to AIC.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Allo-MSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509156
The ClinicalTrials.gov registry entry for NCT02509156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02509156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509156 about?
NCT02509156 is a clinical study titled "Stem Cell Injection in Cancer Survivors". The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC). The secondar...
What is the current status of trial NCT02509156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2016-08. Estimated completion is 2020-04-20.
What interventions are being tested in trial NCT02509156?
The interventions under investigation include: Placebo (BIOLOGICAL), Allo-MSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT02509156?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.